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Network meta-analysis explained
Sofia Dias,1,2 Deborah M Caldwell2
What is NetWork meta-aNalysis?
Healthcare decisions should be based 
on all relevant evidence.1 Usually, this is 
provided by randomised controlled trials 
(RCTs) comparing two or more interven-
tions for a condition affecting a target 
population of interest, although other 
forms of evidence can be considered.1 2 
When more than one study is available, 
meta-analysis can be used to combine 
multiple treatment effects and obtain an 
overall estimate of the effect in the target 
population. To assess clinical effective-
ness, evidence from RCTs is typically used 
and relative treatment effects estimated in 
individual trials are pooled using methods 
that preserve within-trial randomisation. 
However, for the majority of health condi-
tions, there are more than two interven-
tions of interest. In such cases, performing 
multiple pairwise meta-analyses 
(comparing interventions two at a time) 
or lumping every active intervention to be 
compared with a ‘control’ is of limited use 
for decision-making and does not allow 
for coherent and transparent decisions. 
Decisions involving >20 interventions 
are not uncommon.3–6 The number of 
pairwise comparisons required to make a 
decision between 3 interventions is 3, with 
5 interventions it is 10, with 10 interven-
tions it is 45 and with 41 interventions4 
it is 820. Clearly, not all comparisons will 
have been carried out in RCTs but looking 
at multiple separate pairwise analyses 
carried out using different sets of trials 
makes it impossible to decide which inter-
vention is best.
Network meta-analysis (NMA), also 
termed multiple treatment meta-analysis 
or mixed treatment comparisons, was 
developed as an extension of pairwise 
meta-analysis to allow comparisons of 
more than two interventions in a single, 
coherent analysis of all the relevant 
RCTs.7–10 Its main advantages are that it 
produces consistent estimates of the rela-
tive effects of all interventions compared 
with every other in a single analysis using 
both direct and indirect evidence, while 
also correctly incorporating the relative 
effects from trials with more than two 
arms (ie, avoiding double counting of 
patients). This results in greater precision 
of treatment effect estimates and the ability 
to rank all the interventions in a coherent 
way.8 As for standard meta-analysis, NMA 
can be performed for most types of RCT 
outcomes, continuous, dichotomous, 
event rates and from survival models, 
using an appropriate scale (mean differ-
ence (MD), OR, relative risk, HR, etc).
The underlying idea is very simple: 
consider three friends, Anne, Ben and 
Charles. If we know that Ben is 7 cm taller 
than Anne, and that Charles is 10 cm taller 
than Anne, then we know that Charles 
is 3 cm taller than Ben, and is therefore 
the tallest. We can also rank the friends 
in terms of who is tallest as 1=Charles, 
2=Ben, 3=Anne. So, by taking Anne’s 
height as reference and measuring the 
heights of the others compared with hers, 
we know how everyone’s height compares 
to each other and how to order the friends 
by height. The only assumption being 
made is that the heights we measured are 
an accurate reflection of the true heights 
of the three friends (in other words, we 
used a sufficiently accurate measuring 
tool). It is easy to see that the same relative 
heights and ranks would be obtained if 
one of the male friends had been the refer-
ence, and how the height relationships 
would extend if more than three friends 
had been measured. This is exactly how 
NMA works, although we also take the 
uncertainty (ie, the sampling error) in the 
relative effect estimates into account, as is 
standard in meta-analysis.
Suppose we are interested in comparing 
treatments B and C. We find one trial 
comparing B with A, giving an MD of 
−2.3 with an SE of 0.45 and one trial 
comparing C with A giving an MD of 
−4 with an SE of 0.5. This suggests that 
both treatments B and C are better than 
A with 95% CIs that exclude no effect: 
(−3.18 to –1.42) for B compared with 
A and (−4.98 to –3.02) for C compared 
with A (assuming a reduction in the mean 
is desirable, eg, for pain). The network 
formed by these comparisons is given in 
figure 1. In the absence of a direct RCT, 
what can we say about the relative effect 
of treatment C versus B? The first thing 
to note is that this question can only be 
answered in the context of a predefined 
patient population of interest. That is, one 
must ensure that the populations included 
in the B versus A and the C versus A trials 
are comparable to each other and to our 
target population, with respect to any 
potential effect modifying characteris-
tics.10 Once it is decided that these studies 
were carried out on clinically homoge-
neous populations (which, in turn, are 
similar to the target population) then it can 
be assumed that each study estimates the 
true treatment effects in the target popula-
tion (ie, the relative effects were measured 
using an ‘accurate measurement tool’). We 
can therefore say that C is better than B by 
1.7 units through the indirect comparison 
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Figure 1 An example of a network of three treatments compared in two trials (solid black lines), 
where an indirect comparison can be made (dashed grey line). MD, mean difference.
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of treatments C and B,11 since the true 
treatment effects of B versus A, C versus 
A and C versus B must be consistent, 
that is, they must add up in the same way 
as the friends’ heights. In other words, the 
MD of C compared with B must be the 
difference between the MDs of C versus A 
and B versus A, which is −1.7 units. This 
consistency relationship, sometimes also 
called transitivity, must hold if the studies 
are estimating the true effects in a patient 
population. To obtain a 95% CI for the C 
versus B comparison, we simply add the 
variances of the two other comparisons 
to obtain an SE with which a 95% CI can 
be constructed: (−3.01 to –0.39). This 
type of comparison is termed ‘indirect’ as 
it relies on evidence against the compar-
ator A, and not on ‘direct’ head-to-head 
evidence from one or more trials of C 
versus B.
Suppose now that we also had evidence 
from a new study on the same patient 
population which compared treatment 
C with B, giving an MD of −1.8 95% CI 
(−3.66 to 0.06). Traditional hierarchies of 
evidence state that estimates from direct 
head-to-head RCTs provide the ‘best 
available’ evidence of intervention effects. 
Should we now discard the indirect 
evidence? Or perhaps we should prefer 
the indirect evidence since it suggests a 
statistically significant effect? To do either 
is contrary to the principle of using all 
relevant evidence for decision making.1 12 
The solution is to use both the direct and 
indirect evidence to do a mixed (evidence) 
treatment comparison, or NMA, under 
the assumption that both the direct and 
indirect evidence are estimating the same, 
true, underlying treatment effect of C 
versus B in our target population. The 
exact same principles apply when multiple 
RCTs are available for each of the possible 
comparisons and for more than three 
interventions.
NMA relies on the same assumptions 
underlying pairwise meta-analysis, that 
is, the included studies are sufficiently 
homogenous in terms of the condition 
being studied, the included participants 
and the definition of active and control 
interventions. In other words, we are 
assuming that the effects of B versus A and 
C versus B that would have been observed 
if the C versus A RCT had included all 
three treatments, is the same as that 
observed in the B versus A RCT (apart from 
sample variability). This assumption is the 
basis for coherent decisions whether they 
involve two or more treatments. One way 
to empirically check this is to ask: 'given 
the known study and participant charac-
teristics, if all these studies compared the 
same two treatments, would it be suitable 
to combine them in a meta-analysis?' If the 
answer to this is yes, and the only distinc-
tion is that instead the studies compare 
different sets of interventions, then the 
assumption of ‘sufficient homogeneity’ is, 
in principle, satisfied.
Because NMA pools the relative treat-
ment effects estimated across RCTs, 
within-trial randomisation is preserved. 
As long as the interventions of interest 
form a connected network of compar-
isons, then relative effects of each inter-
vention compared with every other can 
be obtained, along with estimates of their 
uncertainty (eg, 95% CIs). Figure 2 shows 
two networks of tocolytic interventions 
compared in a guideline produced for the 
National Institute for Health and Care 
Excellence,13 which updated a previously 
published systematic review and NMA.14 
Nine types of tocolytic interventions were 
of interest (table 1) and 98 RCTs were 
included. To ensure that the assumption 
of consistency of treatment effects was 
reasonable, the study characteristics and 
possible effect modifiers were first assessed 
by the reviewers.14 For example, the anal-
ysis excluded trials in which women were 
at high risk of preterm delivery such as 
those with multiple gestation and ruptured 
membranes. Underpinning this exercise 
is the need to determine if every indi-
vidual included in every trial across the 
network could have been (hypothetically) 
randomised to any of the included treat-
ments. If, for example, a treatment would 
only be administered to a multiparous and 
not nulliparous woman or as a second-line 
or third-line treatment, it is possible that 
the assumption of consistency might not 
hold.
The first network (figure 2A) includes 
47 RCTs reporting on perinatal death. It is 
‘connected’ as there is a path that connects 
every treatment and therefore all relative 
effects for all interventions compared 
Figure 2 Network plots for (A) perinatal death and (B) estimated gestational age at delivery. The size of the circles is proportional to the number 
of patients randomised to each intervention and width of the lines is proportional to the number of studies making each comparison. Data from 
the National Institute for Health and Care Excellence guideline.13
table 1 Tocolytic therapies of interest
interventions
1 Placebo/control
2 Prostaglandin inhibitors
3 Magnesium sulfate
4 Betamimetics
5 Calcium channel blockers
6 Nitrates
7 Oxytocin receptor blockers
8 Alcohol/ethanol
9 Other treatments
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with every other can be obtained. We can 
see that the interventions with the most 
patients randomised are (in decreasing 
order) betamimetics and placebo, as 
they have the widest circles. The second 
network, (figure 2B), includes the 51 RCTs 
which reported on estimated gestational 
age (EGA) at delivery. This figure has 
two disconnected interventions: ‘alcohol/
ethanol’ and ‘other treatments’ cannot be 
compared with the rest of the network. 
For this outcome, comparisons can only 
be made between the other interventions. 
More information can be added to these 
plots to show other network character-
istics,14 15 although the ability to display 
additional information can be limited by 
the size of the network.
Nma models aNd estimatiNg 
treatmeNt eFFeCts
NMA simultaneously combines the rela-
tive treatment effects estimated within 
each study while accounting for the indi-
vidual treatments being compared and 
correctly incorporating studies with more 
than two arms. Fixed or random effects 
models can be fitted, the latter allows 
for between-study heterogeneity. NMA 
random effects models usually assume 
that the between-study heterogeneity is 
the same across all comparisons, that is, 
a single measure of heterogeneity is calcu-
lated across the whole network, although 
models allowing for different heteroge-
neity for each comparison can also be 
fitted.16 In the presence of large heteroge-
neity, patient or study characteristics that 
may modify the relative treatment effects 
(effect modifying covariates) should be 
investigated using meta-regression17 or 
sensitivity analyses.
As a statistical model, NMA can be 
fitted using a frequentist or Bayesian 
approach.18 A Bayesian approach to NMA 
requires a prior probability distribution to 
be specified for the parameter of interest 
(eg, treatment effect), describing the range 
and probability of plausible values for the 
parameters, which is combined with a 
likelihood statement, which describes the 
data collected, using Bayes theorem. This 
produces a posterior distribution which 
describes the new range and probability 
of plausible values for the parameter, on 
which statistical inferences are based.19 
Uncertainty in the parameters is fully 
represented by their posterior distribu-
tions, so direct probability statements can 
be made on, for example, the probability 
that treatment X increases EGA at delivery 
by 4 weeks. Consequently, Bayesian 
NMAs are more commonly used as they 
naturally produce ranking and probability 
outputs useful for decision-making and 
allow for greater flexibility in the models 
fitted.10 For example, a ‘class model’ can 
be used where interventions that have a 
similar mode of action (ie, belong to the 
same ‘class’) are assumed to have similar, 
but not identical, effects compared with 
the reference treatment as used in the 
tocolytics example13 14 (figure 2 shows 
the networks at class level). This allows 
an overall decision to be made at a class 
level, but individual treatment profiles and 
costs can also be incorporated in clinical 
or health economic decisions.
When data are sparse, for example, for 
adverse or rare events, Bayesian methods 
have additional advantages such as the 
ability to better handle studies with zero 
cells and the potential for including any 
relevant prior information. However, 
for most NMAs only simple models are 
required and no prior information is 
used, with Bayesian approaches typically 
defining non-informative prior distri-
butions for all treatment effect parame-
ters, making results from frequentist or 
Bayesian analyses very similar. The main 
difference between these approaches is 
how results are presented. Results from 
a frequentist NMA will be presented as 
estimated relative effects (eg, MD, OR, 
etc) and a 95% CI, whereas results from 
a Bayesian analysis will be presented as 
summaries from the posterior distribution 
of the MD (or OR), which can be the 
mean or median MD (OR, etc) and their 
95% credible interval (CrI).15 A Crl is 
interpreted as the interval where there is 
a 95% probability that the values of the 
MD (OR, etc) will lie. Medians are recom-
mended for ratio measures such as the 
OR, HR or risk ratio, whereas either the 
mean or median can be reported for the 
MD or standardised MD.
Regardless of the framework used, 
the fit of the model to the data should 
be assessed, and in networks with both 
direct and indirect evidence contributing 
to estimates, the assumption of consis-
tency should also be statistically assessed. 
This can be done by comparing the results 
obtained using the direct evidence alone 
with the results obtained using the indi-
rect evidence alone,20 21 and calculating 
a p value for their difference. Methods 
that assess consistency in the whole 
network22 23 are also available and often 
preferred when networks are large.10 
Should evidence of inconsistency be 
found, the characteristics of all included 
studies should be re-examined and adjust-
ment for effect modifiers (eg, covariates or 
risk of bias) should be considered.
reportiNg aNd iNterpretiNg 
results
Table 2 reports the MDs in EGA (in weeks) 
with their 95% CrIs. Colloquially known as 
a ‘triangle table’, it displays findings from 
different analyses, in this case from the 
direct, pairwise analyses and the NMA anal-
ysis. Values shown in the upper diagonal are 
the MDs for the column header versus the 
row header and are derived from the NMA, 
and values in the lower diagonal are the 
MDs for the row header versus the column 
header. This ensures that the values are 
easily comparable across the two analyses. 
For example, the MD estimated from the 
NMA (upper diagonal) for prostaglandin 
inhibitors versus placebo is 2.32 (95% 
CrI 1.27 to 3.35), suggesting that there is 
evidence that the intervention increases 
table 2 Mean differences and 95% CrI for EGA at delivery (in weeks) from the pairwise and network meta-analyses
. placebo/control
prostaglandin 
inhibitors magnesium sulfate Betamimetics
Calcium channel 
blockers Nitrates
oxytocin receptor 
blockers
Placebo/control 2.32 (1.27 to 3.35) 1.29 (0.29 to 2.27) 1.25 (0.40 to 2.07) 1.69 (0.69 to 2.66) 1.65 (0.52 to 2.78) 0.68 (−1.32 to 2.67)
Prostaglandin inhibitors 3.27 (1.68 to 4.78) −1.04 (−2.01 to –0.04) −1.08 (−2.08 to –0.05) −0.64 (−1.68 to 0.42) −0.67 (−1.97 to 0.67) −1.65 (−3.76 to 0.52)
Magnesium sulfate −0.14 (−1.60 to 1.28) −0.23 (−1.45 to 0.97) −0.04 (−0.99 to 0.91) 0.40 (−0.51 to 1.31) 0.36 (−0.88 to 1.63) −0.61 (−2.69 to 1.50)
Betamimetics 1.91 (0.90 to 2.90) −1.56 (−3.42 to 0.28) −0.19 (−2.78 to 2.45) 0.44 (−0.32 to 1.20) 0.40 (−0.54 to 1.37) −0.57 (−2.58 to 1.47)
Calcium channel blockers na −0.53 (−2.32 to 1.25) −0.02 (−1.25 to 1.22) 0.80 (−0.08 to 1.67) −0.03 (−1.16 to 1.10) −1.01 (−2.98 to 0.99)
Nitrates 0.17 (−1.72 to 2.06) na na −0.58 (−0.47 to 1.67) 1.30 (−1.07 to 3.68) −0.98 (−3.15 to 1.21)
Oxytocin receptor blockers 0.90 (−1.74 to 3.53) na na na −1.21 (−3.66 to 1.23) na
The upper diagonal displays the mean differences for the column intervention vs the row intervention, derived from the NMA. Values >0 favour the column defining intervention. The lower diagonal displays the mean differences for the row 
intervention vs the column intervention, derived from direct comparisons only. Values >0 favour the row defining the intervention.
Adapted from the National Institute for Health and Care Excellence guideline.13
Crl, credible interval; EGA, estimated gestational age; na, not available; NMA, network meta-analysis.
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EGA at delivery, by 2.3 weeks, compared 
with placebo. In addition, we can say that 
there is a 95% probability that this increase 
is between 1.27 and 3.35 weeks. We can 
compare this with the MD estimated from 
the direct evidence alone (lower diagonal) 
3.27 (95% CrI 1.68 to 4.78). The first thing 
to note is that the point estimates are close 
and the 95% CrIs overlap considerably. 
However, the 95% CrIs from the NMA 
are more precise. In contrast, the MD of 
magnesium sulfate compared with placebo 
estimated from the direct evidence and the 
NMA appear contradictory, with estimates 
in opposite direction, although the very 
wide 95% CrI for the pairwise meta-anal-
ysis overlaps with those obtained from 
the NMA, which are also narrower. The 
consistency assumption was checked13 and 
some evidence of conflict between direct 
and indirect evidence was identified for this 
comparison (indirect OR=1.29 (95% CrI 
0.29 to 2.27), p=0.015). No explanation 
was found for this conflict, but it was taken 
into account when making decisions.
The empty cells in the lower diagonal 
denote that no direct evidence was available 
for that comparison (eg, calcium channel 
blockers vs placebo), whereas the NMA can 
make all the comparisons and show that 
there is evidence of an increase in EGA at 
delivery for all interventions compared with 
placebo, except oxytocin receptor blockers 
(MD 0.68, 95% CrI −1.32 to 2.67).
Triangle tables can also be used to report 
two different outcomes, with one in the top 
half and the other in the bottom half. This 
can be a good way to display results from 
two important outcomes, for example, 
effectiveness and acceptability24 or other 
closely related outcomes,4 although it can 
be limited by the required width when 
there are many interventions. Similar 
vertical displays can convey the same infor-
mation14 15 and relative effects can also be 
presented as forest plots.13 14
Table 3 shows treatment rankings and 
the probability that each intervention (or 
class) is the ‘best’ or in the top three for 
EGA at delivery. Here ranks are reported 
for effectiveness, such that rank 1 means 
the intervention is most effective. Placebo 
has a mean rank of 6.74 and a median rank 
of 7 (95% CrI 6 to 7). That is, on average, 
placebo was ranked approximately seventh 
out of seven treatments (ie, worst) for 
gestational age at delivery. Conversely, 
prostaglandin inhibitors were ranked first 
out of all seven treatment classes and had 
a 74% probability of being the most effec-
tive treatment and a 97% probability of 
being in the top three treatment classes to 
increase EGA.
An alternative way of reporting ranks 
is to consider the cumulative probabilities 
using the surface under the cumulative 
ranking curve (SUCRA),25 which trans-
forms the cumulative probabilities into 
a single value between 0 and 1, where a 
larger value indicates the more effective 
treatment. This is often reported as a 
percentage.15
All probabilities, SUCRA values and 
rankings should be interpreted with caution 
as they are very sensitive to the uncertainty 
in the relative treatment effects used to 
produce them. Measures or displays which 
capture this uncertainty such as a table of 
rank statistics with 95% CrI (table 3), rank 
probability plots (rankograms)10 14 25 or 
cumulative ranking probability plots15 25 
should be reported in preference to single 
values such as the probability of being 
best or SUCRA. It is also imperative that 
ranking results are considered alongside the 
estimates of relative treatment effects as a 
treatment could have a higher rank without 
evidence of having a better effect than any 
of the others.
Importantly, all results should be inter-
preted taking into account the uncertainty 
in the estimates (conveyed by the 95% CrI) 
as well as the risk of bias in the included 
evidence. Tools that allow an examination 
of the impact of studies at risk of bias,26 27 
and the impact of changes in the evidence 
on the decision28 have been developed and 
can help to interpret the findings from an 
NMA.
CoNClusioNs
When more than two interventions are 
being considered, synthesis of RCTs using 
an NMA will ensure that all the relevant 
evidence, whether direct or indirect, is used 
to produce coherent estimates of the rela-
tive effects of every intervention compared 
with every other. This allows for more effi-
cient use of the relevant evidence, which 
can increase the precision of the estimates. 
In addition, because multiple sources of 
evidence are used, the final estimates are 
more robust than if only direct sources of 
evidence were included, that is, they are less 
likely to be influenced by the inclusion or 
exclusion of a single trial. The underlying 
assumption is that there are no participant 
or study characteristics that would modify 
the relative treatment effect of each treat-
ment compared with every other.
Relying on multiple pairwise meta-anal-
yses, each including a different set of trials 
may lead to incoherent decisions and does 
not make the best use of the available 
evidence.
It is important to display NMA results 
carefully to aid interpretation and to clini-
cally and statistically assess the plausibility 
of the assumptions made.
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table 3 Posterior rank statistics and probabilities for the outcome EGA at delivery
interventions
rank statistics probabilities
mean median 95% Cri Best top 3
Placebo/control 6.74 7 (6 to 7) 0.00 0.00
Prostaglandin inhibitors 1.38 1 (1 to 4) 0.74 0.97
Magnesium sulfate 4.26 4 (2 to 6) 0.01 0.28
Betamimetics 4.48 5 (2 to 6) 0.00 0.16
Calcium channel blockers 2.84 3 (1 to 5) 0.07 0.76
Nitrates 3.04 3 (1 to 6) 0.13 0.65
Oxytocin receptor blockers 5.27 6 (1 to 7) 0.05 0.19
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